Dr. Bradley S. Galer, MD
Dr. Galer has served as Zogenix Executive Vice President and Chief Medical Officer since December 2013, where he was involved in the licensing and global development of fenfluramine (FINTEPLA) for the treatment of rare devastating childhood-onset epilepsies, including Dravet syndrome and Lennox Gastaut syndrome. Prior to joining Zogenix, Dr. Galer served as President at Nuvo Research, a specialty pharmaceutical company with three commercialized topically delivered pain products. From 2000-2005 Dr. Galer was Endo Pharmaceuticals’ Senior Medical Officer and Group Vice President, Scientific Affairs. Prior to joining industry, Dr. Galer was on faculty at University of Washington and Albert Einstein College of Medicine. He has published over 200 articles in peer review journals and textbooks. Dr. Galer received his medical doctorate and a neurology residency from Albert Einstein in New York and two Fellowships, at Memorial Sloane-Kettering in New York and University of California San Francisco. Dr. Galer offers Sentrimed significant scientific, medical, and product development experience.